Mackay Shields LLC’s Pacira BioSciences PCRX Stock Holding History

Mackay Shields LLC’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-62,085	Closed	-$3.73M	–	1570
2020 Q3	$3.73M	Sell	62,085 -11,900	-16%	-$691K	0.03%	519
2020 Q2	$3.88M	Sell	73,985 -6,400	-8%	-$267K	0.03%	488
2020 Q1	$2.69M	Sell	80,385 -6,800	-8%	-$282K	0.02%	545
2019 Q4	$3.95M	Sell	87,185 -20,800	-19%	-$883K	0.03%	561
2019 Q3	$4.11M	Buy	107,985 +10,100	+10%	+$403K	0.03%	585
2019 Q2	$4.26M	Buy	97,885 +54,088	+123%	+$2.3M	0.03%	592
2019 Q1	$1.67M	Buy	43,797 +7,200	+20%	+$281K	0.01%	781
2018 Q4	$1.57M	Sell	36,597 -57,203	-61%	-$2.67M	0.01%	751
2018 Q3	$4.61M	Sell	93,800 -24,700	-21%	-$1.07M	0.04%	459
2018 Q2	$3.8M	Buy	118,500 +108,000	+1,029%	+$3.73M	0.03%	560
2018 Q1	$327K	Buy	+10,500	New	+$374K	﹤0.01%	1176

Other funds holding PCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

SCM

Spyglass Capital Management San Francisco, California $1.85B AUM 15.7% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Mackay Shields LLC's PCRX Position: Q4 2020 in Review

Mackay Shields LLC sold out of Pacira BioSciences (PCRX) in Q4 2020, closing a stake of 62,085 shares — an estimated $3.73M sold.

Mackay Shields LLC first reported a position in PCRX in Q1 2018 and held it in 11 quarters. The position peaked at $4.61M in Q3 2018. 260 funds tracked by Wall St. Rank hold PCRX as of Q4 2020.

Mackay Shields LLC reported no remaining Pacira BioSciences position as of Q4 2020 after selling out during the quarter.
Mackay Shields LLC sold 62,085 Pacira BioSciences shares in Q4 2020, an estimated $3.73M.
Mackay Shields LLC first reported a position in Pacira BioSciences in Q1 2018 and held it in 11 quarters.
Mackay Shields LLC's Pacira BioSciences position peaked at $4.61M in Q3 2018.
260 funds tracked by Wall St. Rank held Pacira BioSciences as of Q4 2020.

Based on Mackay Shields LLC's 13F filing for Q4 2020, filed 16 Feb 2021.